Press Releases Year None20202019201820172015 August 5, 2020 ORIC Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Update August 5, 2020 ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics August 3, 2020 ORIC Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call June 22, 2020 ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at the 2020 American Association for Cancer Research Virtual Annual Meeting II June 9, 2020 ORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of Directors May 27, 2020 ORIC Pharmaceuticals Announces Five Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II May 26, 2020 ORIC Pharmaceuticals to Present at the Jefferies 2020 Global Healthcare Conference May 20, 2020 ORIC Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results April 28, 2020 ORIC Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares April 27, 2020 ORIC Pharmaceuticals Presents Preclinical Data on CD73 Inhibitor at the American Association for Cancer Research (AACR) Virtual Annual Meeting Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 15
